US20090305996A1 - Use of non-digestable sacharides for giving an infant the best start after birth - Google Patents

Use of non-digestable sacharides for giving an infant the best start after birth Download PDF

Info

Publication number
US20090305996A1
US20090305996A1 US12/282,302 US28230207A US2009305996A1 US 20090305996 A1 US20090305996 A1 US 20090305996A1 US 28230207 A US28230207 A US 28230207A US 2009305996 A1 US2009305996 A1 US 2009305996A1
Authority
US
United States
Prior art keywords
saccharide
infant
composition
digestible
birth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/282,302
Other languages
English (en)
Inventor
Christopher Beermann
Jan Knol
Martine Sandra Alles
Bernd Stahl
Günther Boehm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nutricia NV filed Critical Nutricia NV
Assigned to N.V. NUTRICIA reassignment N.V. NUTRICIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ALLES, MARTINE SANDRA, KNOL, JAN, BEERMANN, CHRISTOPHER, BOEHM, GUNTHER, STAHL, BERND
Publication of US20090305996A1 publication Critical patent/US20090305996A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a composition for stimulating health of an infant by administering the composition to a pregnant woman.
  • LC-PUFA Long chain poly-unsaturated fatty acids
  • EP1296694 relates to prophylaxis of allergies, and relates specifically to primary prevention of atopic diseases by administering probiotic bacteria, beneficial microbes present in a healthy gut flora, pre- and postnatal to children at high risk of atopic diseases.
  • the inventors have found that administration of a water-soluble, non-digestible saccharide to pregnant women improves the immune system of the unborn infant. It was found that the unborn child has an enhanced expression of the receptors CD14, and TLR 2 as present in the membrane of enterocytes and monocytes.
  • the inventors have found that the intestinal flora development of the infant is improved as a result of an improved intestinal and/or vaginal flora of the mother ingesting the present saccharide.
  • the growth of bifidobacteria and lactobacilli in the gastrointestinal tract of the mother is stimulated.
  • the vaginal flora of the mother is also beneficially changed towards a high content and diversity of the bifidobacteria and lactobacilli.
  • the neonatal gut is first inoculated by maternal vaginal and intestinal microflora.
  • an advantageous vaginal and intestinal flora of the mother results in an improved flora of the infant in the first period of life.
  • the infant has reduced chances to develop immune related disorders, such as atopic diseases, but also gastro-intestinal disorders, such as infections, intestinal inflammation, diarrhoea or constipation.
  • this non-digestible saccharide beneficially affected the immune system of the pregnant women and/or of the infants. It was found that the child immune system before delivery is primed towards a faster Th1 response after birth. As a result the chances to develop immune related disorders, such as atopic diseases, is even further reduced.
  • the present invention provides the use of a water soluble, non-digestible saccharide for the manufacture of a composition for
  • the present invention further provides the use of water soluble, non-digestible saccharide for the manufacture of a composition for
  • the composition used in the present method comprises water soluble, non-digestible saccharides.
  • non-digestible refers to saccharides which are not digested in the intestine by the action of acids or digestive enzymes present in the human upper digestive tract (small intestine and stomach), but which are fermented by the human intestinal flora. Mono- and disaccharides such as glucose, galactose, fructose, sucrose and lactose are digestible.
  • the term “fermentable” as used herein refers to the capability to undergo conversion by micro-organisms in the lower part of the gastro-intestinal tract (e.g. colon) to smaller molecules, in particular short chain fatty acids and lactate.
  • the present saccharide is water-soluble, which can be determined with the method described by L. Prosky et al, J. Assoc. Anal. Chem. 71: 1017-1023, 1988.
  • the present saccharides preferably have a degree of polymerisation (DP) of at least 2 and preferably below 100 monosaccharide units, preferably below 60, even more preferably below 40, most preferably below 10.
  • DP degree of polymerisation
  • the present water soluble, non-digestible saccharide is a galactose comprising saccharide.
  • a saccharide with a relatively low degree of polymerisation has an improved fermentability by lactobacilli and/or bifidobacteria and further does not have the technological disadvantage to increase the viscosity.
  • the present saccharide is preferably a water soluble, non-digestible galactose containing saccharide (hereinafter referred to as “GAL-oligo”), which preferably comprise at least 50% galactose units based on the total number of monosaccharide units of the saccharide.
  • GAL-oligo has an improved bifidogenic effect compared to other water soluble, non-digestible saccharides.
  • Human breast milk also comprises a high concentration of GAL-oligo and infants fed human breast milk have an intestinal flora more rich in bifidobacteria than infants fed a standard infant milk formula.
  • the present GAL-oligo contains at least 60% galactose units based on the total number of monosaccharide units present in the saccharide, more preferably, at least 65%.
  • the present GAL-oligo preferably comprises at least two terminal saccharide units, wherein at least one terminal saccharide unit is selected from the group consisting of glucose and galactose; and at least one terminal saccharide unit is selected from the group consisting of galactose and fucose.
  • at least 75% of the saccharides of the GAL-oligo are ⁇ -linked, preferably 100%.
  • terminal saccharide refers to a saccharide which is bound to one other saccharide unit (e.g. galactose, glucose, fructose or fucose).
  • the present GAL-oligo preferably contains not more than 4 terminal saccharides, preferably not more than 2.
  • the GAL-oligo comprises at least one terminal galactose and one selected from at least terminal glucose and one terminal fucose.
  • the present GAL-oligo comprises at least one terminal galactose and at least one terminal glucose.
  • the present Gal-oligo contains 2 terminal saccharide units and has a degree of polymerisation (DP) of 2 to 60.
  • the GAL-oligo is selected from the group consisting of transgalactooligosaccharides, galactooligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT.
  • the GAL-oligo is sialylated.
  • the GAL-oligo is selected from the group consisting of sialyllactose, sialylfucosyllactose, sialyllactosamine and sialyl-LNT and sialyl-neo-LNT, more preferably sialyllactose.
  • the present method comprises the administration of transgalactooligosaccharides ([galactose] n -glucose; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, . . . , 59, 60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10).
  • the saccharides of the transgalactooligosaccharides are ⁇ -linked.
  • Transgalactooligosaccharides are for example present in a composition sold under the trademark VivinalTM (Borculo Domo Ingredients, Netherlands).
  • VivinalTM Bosculo Domo Ingredients, Netherlands.
  • Other suitable sources of TOS are Cup-oligo and Bi 2 muno.
  • the present composition preferably comprises two different water soluble, non-digestible saccharides, differing from each other in structure.
  • Each water soluble, non-digestible saccharide is fermented by different species of micro-organisms in the intestinal and/or vaginal flora and/or on a different location in the intestinal tract, resulting in an improved flora and greater diversity of bacteria.
  • the present invention provides a composition which preferably comprises water soluble, non-digestible saccharide A and water soluble, non-digestible saccharide B.
  • Saccharide A and saccharide B have different glycosidic linkages, a different degree of polymerisation and/or a different monosaccharide composition.
  • saccharide A is a GAL-oligo.
  • the percentage of at least one monosaccharide unit selected from the group consisting of glucose, fructose and galactose in saccharide A is at least 40% higher than the percentage of the same monosaccharide unit in saccharide B, preferably at least 50%, more preferably at least 75%, even more preferably at least 90%.
  • An increased diversity of monosaccharide units stimulates a wider population of intestinal (beneficial) bacteria, resulting in an improved flora.
  • the percentage of a monosaccharide unit in the saccharide can be simply calculated by dividing the number of the respective monosaccharide units (e.g. glucose) present in the saccharide by the total number of the monosaccharide units present in that saccharide.
  • water soluble, non-digestible saccharide A and B have a degree of polymerisation (DP) between 2 and 200.
  • DP degree of polymerisation
  • the lower DP advantageously reduces viscosity and increases fermentability of the non-digestible saccharides.
  • % of the cumulative weight of water soluble, non-digestible saccharides A and B has a DP of 2 to 8.
  • the DP of water soluble, non-digestible saccharide A is at least 5 monosaccharide units lower than the DP of water soluble, non-digestible saccharide B, preferably at least 10, even more preferably at least 15.
  • Including a saccharide with an increased degree of polymerisation reduces the osmotic load, and results in a prolonged fermentation along the colon, thereby improving stimulation of beneficial bacteria also in more distal parts of the colon.
  • water soluble, non-digestible saccharide A has a DP of 2-10, more preferably 2-8.
  • the water soluble, non-digestible saccharide B has DP of 11-100.
  • the water soluble, non-digestible saccharides A and B with a different DP may have the same or slightly different monosaccharide composition, preferably different monosaccharide compositions.
  • the percentage of at least one glycosidic linkage of water soluble, non-digestible saccharide A based on total glycosidic linkages of present in saccharide A is at least 40% higher than the percentage of the same glycosidic linkage in water soluble, non-digestible saccharide B, preferably at least 50%, even more preferably at least 75%.
  • glycosidic linkage refers to a C—O—C bond formed between the rings of two cyclic monosaccharide units by the elimination of water. An increased diversity in glycosidic linkages stimulates a wider range of beneficial bacteria.
  • Glycosidic linkages differ in that they covalently bind carbon atoms in the monosaccharide units at differently numbered positions, and/or that they form a or P bonds.
  • Examples of different glycosidic linkages occurring in water soluble, non-digestible saccharides are ⁇ (1,3), ⁇ (1,4), ⁇ (2,1), ⁇ (1,2), and ⁇ (1,4) linkages.
  • the glycosidic linkages in water soluble, non-digestible saccharide A comprises at least 40% ⁇ (1,4) glycosidic linkages, more preferably at least 75%.
  • the glycosidic linkages in water soluble, non-digestible saccharide B preferably comprise at least 40% ⁇ (2,1) glycosidic linkages, more preferably at least 75%.
  • the present composition contain a combination of Gal-oligo and a water soluble, non-digestible saccharide selected from the group consisting of fructopolysaccharides (such as inulin), more preferably a combination of GAL-oligo which have an average DP between 2 and 10 and a water soluble, non-digestible saccharide selected from the group consisting of fructopolysaccharides and fructooligosaccharides, most preferably a combination of transgalactooligosaccharides and inulin.
  • a water soluble, non-digestible saccharide selected from the group consisting of fructopolysaccharides (such as inulin)
  • GAL-oligo which have an average DP between 2 and 10
  • a water soluble, non-digestible saccharide selected from the group consisting of fructopolysaccharides and fructooligosaccharides, most preferably a combination of transgalactooligosaccharides and inulin.
  • saccharide A and saccharide B are in a weight ratio of 3/97 to 97/3, more preferably 5/95 to 95/5. Having both saccharide A and B present in a sufficient relative proportion will have a better effect on flora. Most preferably the weight ratio of saccharide A to B is 2/3 to 95/5. A slight excess of saccharide A, being preferably a GAL-oligo and/or an oligosaccharide, is even further preferred as this will have a better effect on the flora.
  • the present composition additionally comprises long chain polyunsaturated fatty acids and/or long chain polyunsaturated fatty acyl chains (LC-PUFA).
  • LC-PUFA in the present invention relates to a fatty acid or fatty acyl chain with a length of 20 carbons or more and at least two unsaturated bonds.
  • the composition comprises a LC-PUFA selected from the group consisting of eicosapentaenoic acids and/or acyl chain (EPA), docosahexaenoic acid and/or acyl chain (DHA) and arachidonic acid and/or acyl chain (AA).
  • EPA eicosapentaenoic acids and/or acyl chain
  • DHA docosahexaenoic acid and/or acyl chain
  • AA arachidonic acid and/or acyl chain
  • the composition comprises DHA.
  • the composition comprises AA.
  • the composition comprises DHA and AA.
  • LC-PUFA advantageously strengthen the immune system of the infant to be born.
  • administration of a composition comprising both a water soluble, non-digestible oligosaccharide and LC-PUFA to a pregnant women will have an improved effect on the immune system of the infant compared to the water soluble, non-digestible saccharide alone.
  • the weight ratio EPA/DHA is preferably 1 or lower, more preferably below 0.5.
  • the LC-PUFA may be provided as free fatty acids, in triglyceride form, in phospholipid form, or as a mixture of one of more of the above.
  • the present composition preferably comprises at least one of AA and DHA in phospholipid form.
  • the weight ratio DHA to AA is between 0.1 and 20, more preferably between 0.5 and 5.
  • the composition comprises 50 to 3000 mg LC-PUFA per daily dose, more preferably 100 to 1500 mg, most preferably 200 to 500 mg.
  • the composition additionally comprises probiotics.
  • Probiotics in the present invention refer to micro-organisms, which upon administration exert a beneficial effect on the host. Probiotics have beneficial effects on intestinal flora, vaginal flora and/or the immune system of pregnant women and their infant to be born, hence the combination of a water soluble, non-digestible saccharide and probiotics will have a superior effect on intestinal flora and/or immune system of both.
  • the probiotics are selected from the group consisting of Lactobacillus and Bifidobacterium . More preferably, the probiotic is selected from the group consisting of the Lactobacillus accidophilus group, L. rhamnosus, L.
  • the probiotics are L. paracasei and/or B. breve , since administration of water soluble, non-digestible saccharide stimulates most species of Lactobacillus and Bifidobacterium population to an equal extent, but stimulates B. breve and L. paracasei to a lesser extent. Since bifidobacteria are more dominant in the infant intestinal flora than lactobacilli, B.
  • probiotics are present in a daily dose of 1 ⁇ 10 6 colony forming units (cfu) to 1 ⁇ 10 13 cfu, more preferably 1 ⁇ 10 7 to 1 ⁇ 10 1 , most preferably 1 ⁇ 10 8 to 1 ⁇ 10 10 of each different probiotic.
  • cfu colony forming units
  • the composition comprises additionally vitamins and minerals beneficial for pregnant women. Often, supplements comprising vitamins and minerals are ingested by pregnant women for their or the foetus' benefit. Inclusion of these vitamins and minerals in the present composition conveniently reduces the amount of compositions to be taken by pregnant women.
  • the composition comprises at least one component, more preferably at least three components, most preferably at least six components selected from the group consisting of folic acid, vitamin B1, vitamin B2, vitamin B6, vitamin A, vitamin D, iron, zinc, and iodine.
  • these components are present in a daily dose of 25 to 100% of the recommended daily allowance (RDA), more preferably between 45 to 100%.
  • RDA recommended daily allowance
  • vitamin A is supplied as ⁇ -carotene.
  • composition comprising the water soluble, non-digestible saccharide may be administered to the pregnant women in the form of a bar, a capsule, a tablet, a liquid, or a powder.
  • the composition is a milk-based liquid, comprising fats, proteins and digestible carbohydrates.
  • the fat content of the milk-based liquid is less than 2 g/l in order to keep the amount of calories to be consumed low.
  • this milk-based liquid is packed into a bottle or tetrapack with a volume of 50 to 1000 ml, more preferably 60 to 500, most preferably 75 to 125 ml.
  • the composition is a bar, i.e. a solid, chewable composition with a water activity below 0.8, preferably below 0.65.
  • the composition is a powder, packed in sachet comprising 1 to 10 g, more preferably 1.5 to 7 g, most preferably 2 to 5 g.
  • the present saccharide is administered to the pregnant women in an amount between 0.5 and 50 g per day, preferably between 3 and 25 g per day, most preferably between 6 and 12 g per day.
  • this daily dose is administered in one portion per day.
  • this daily dose is divided over 2 or 3 or 4 portions, which are consumed 2, 3 or 4 times per day, respectively.
  • the composition is administered to the pregnant women at least 2 weeks before due delivery, more preferably at least 6 weeks, most preferably at least 12 weeks.
  • a method for improving the intestinal flora and/or the immune system of an infant comprising administering the composition of the present invention, i.e. a composition comprising water soluble, non digestible saccharides, to a woman pregnant of said infant.
  • the composition of the present invention i.e. a composition comprising water soluble, non digestible saccharides
  • the immune system of the infant is strengthened.
  • Strengthening the immune system in the present invention relates to improvement, stimulation and/or enhancement of the immune system.
  • the improvement, stimulation and/or enhancement is with respect to a control group, which in the context of this invention means with respect to a pregnant woman that did not ingest water soluble, non-digestible saccharide.
  • the inventors observed that administration of a water soluble, non-digestible saccharide directed the neonatal immune system towards a Th1 response and/or improved the Th1/Th2 balance. It was found that before delivery the immune system of the unborn child is primed by enhancing the receptors CD14 and TLR 2.
  • administration of water soluble, non-digestible saccharide to pregnant women is used for preventing the onset of atopic diseases in the infant.
  • the composition is administered to pregnant women in order to prevent the incidence and/or reduce the severity of allergy (i.e. food allergy), eczema (i.e. atopic dermatitis), asthma, rhinitis, hayfever, rhinoconjunctivitis, and/or wheezing in the infant, most preferably allergy and/or atopic dermatitis.
  • eczema i.e. atopic dermatitis
  • asthma rhinitis
  • hayfever hayfever
  • rhinoconjunctivitis hayfever
  • wheezing in the infant, most preferably allergy and/or atopic dermatitis.
  • Eczema i.e. atopic dermatitis, is characterized by a dry and/or red and/or an itchy skin.
  • administration of the water-soluble, non-digestible saccharide to the pregnant women is used to improve the intestinal flora of the infant.
  • Administration of the present composition is in an embodiment used for enhancing the percentage bifidobacteria and/or lactobacilli in the colon and/or faeces based on total bacteria present in the flora and/or faeces of the infant after birth.
  • a flora rich in bifidobacteria and/or lactobacilli strengthens the immune system of the infant and improves the gastro-intestinal health.
  • An improved gastro-intestinal health relates to a reduced incidence of gastro-intestinal infections, a shorter duration of intestinal infections, a reduced incidence and severity of gastro-intestinal inflammation, a reduced incidence and/or severity of diarrhoea, reduced constipation, or reduced cramps compared to the gastro-intestinal health of an infant of which the mother during pregnancy did not ingest the present composition comprising water-soluble, non-digestible saccharide.
  • Strengthening or strengthened and improving or improved in the context of this invention is relative to an infant of which the mother during pregnancy did not ingest the present composition comprising water-soluble, non-digestible saccharide or relative to a pregnant woman that did not ingest the present composition comprising water-soluble, non-digestible saccharide.
  • a strengthened immune system will have a preventive effect on atopic diseases and/or respiratory infections.
  • administration of the present composition to a pregnant woman is used to prevent and/or reduce the severity of disorders selected from the group consisting of allergy (i.e. food allergy), eczema (i.e atopic dermatitis), asthma, rhinitis, hayfever, rhinoconjunctivitis, wheezing, intestinal infections, vaginal infections, respiratory infections, diarrhoea, constipation, cramps and intestinal inflammation in the infant after birth.
  • administration of the present composition to a pregnant woman is used to prevent disorders selected from the group consisting of intestinal infections, respiratory infections, diarrhoea, constipation, cramps and/or intestinal inflammation of the infant after birth.
  • Packages comprising the present composition according to the invention with a text stating that upon consumption of the composition a pregnant woman will give her child the best start after birth, for example regarding intestinal colonisation, intestinal flora, flora composition and/or immune system, e.g. immunological defense or strengthened or improved or enhanced or stimulated immunity are also encompassed.
  • composition of the invention is in one embodiment used to improve the immune system of the pregnant women.
  • composition of the present invention comprising water soluble, non-digestible saccharides, preferably comprising two different water soluble, non-digestible saccharides
  • administration of the present composition is used to enhance the percentage of lactobacilli and/or bifidobacteria based on total bacteria present in the intestine and/or vagina of the pregnant women. This is of importance since a disturbed vaginal flora is frequently found during pregnancy and the overgrowth of pathogens and breakdown of the vaginal microbial microenvironment can be prevented by a stable colonization with lactobacilli.
  • CA prospective, double-blind, randomized, placebo controlled study with a parallel group design was performed with a total of 33 pregnant healthy volunteers. They received either the experimental supplement or a placebo from the 25th week of gestation until delivery.
  • the experimental supplement was based on non-digestible oligosaccharides, and comprised 3 g of GOS (from Vivinal GOS, Borculo Domo, The Netherlands) plus inulin (RaftilinHP, Orafti, Belgium), in a 9:1 wt/wt ratio and 3 g of digestible maltodextrin. This supplement was taken 3 times a day.
  • the control supplement was composed of 6 g digestible maltodextrin.
  • a stool sample was taken before the first supplementation, at the 25th week of gestation.
  • a second stool sample was taken at the last standardized routine hospital visit before delivery.
  • one cord blood sample was obtained from the placental umbilical vein.
  • day 5 and 6 month after delivery stool samples were obtained from the neonates.
  • CB Cord blood
  • NKT cells frequency of monoclonal T cell receptors (i.e. homogeneous N-region of Va24JaQ TCR, quantification of Toll-like receptor expressing cells (TLR2, TLR4); granulocytes count.
  • TLR2, TLR4 Toll-like receptor expressing cells
  • Lymphocyte subsets were by four-color-cytometry. Characterization of the TH1/TH2-related mRNA cytokine and chemokine receptor patterns (TNF-a, INF-g, IL-4, IL-8, IL10, IL-12, IL-13, TGF ⁇ , CD25, CD45RO, CD45RO, CTLA-4, CCR3, CCR4, CCR5, CXCR3) in non-stimulated cells were determined by Real-time RT PCR and after whole blood stimulation with ConA/PHA and LPS ex vivo. Analysis of the ratio of TH1/TH2-cytokine production within CD4 + and CD8 + T-cell subsets were determined.
  • Placental cortical blood samples were obtained form 28 deliveries and stimulated with ConcanavalinA (ConA)/(PHA), Lipopolysaccharide (LPS), Staphylococcus enterotoxin B (SEB), ⁇ -lactoglobulin (BLG), major house dust mite allergen from Dermatophagoides pteronyssinus (Der p1), ovalbumin (Ova), for 24 h.
  • ConcanavalinA ConcanavalinA
  • PPS Lipopolysaccharide
  • SEB Staphylococcus enterotoxin B
  • BLG ⁇ -lactoglobulin
  • Major house dust mite allergen from Dermatophagoides pteronyssinus Dermatophagoides pteronyssinus
  • ovalbumin ovalbumin
  • CB T lymphocytes (50 ⁇ L whole blood samples) were stained with appropriately diluted FITC-, PE-, PC5-, or APC-labeled monoclonal antibodies against human CD4, CD8, CD45RO, CD45RO, CD25, CD69, CCR4, CCR5, CD14, CCR1, CCR2, CCR6, CCR7, CCR8, CCR9, CXCR3, CXCR4, CXCR5, CRTH2, and appropriate isotype controls. After staining, contaminating erythrocytes were lysed.
  • CKR + chemokine receptor
  • Th T helper
  • MFI mean fluorescence intensity
  • Heparinized CB was diluted 1 to 5 in RPMI-1640. Aliquots of 1 mL diluted CB were stimulated with concavalin A (Con A 50 ⁇ g/mL), beta-lactoglobulin (100 ⁇ g/mL BLG), ovalbumin (100 ⁇ g/mL OVA), lipopolysaccharid (0.1 ⁇ g/mL LPS), staphylococcal enterotoxin B (0.1 ⁇ g/mL SEB), Dermatophagoides pteronyssinus (10 ⁇ g/mL Der p1) or medium alone in a 24-well culture plate. Cells were incubated at 37° C. in a 5% CO 2 -atmosphere for 24 h or 48 h and supernatants were stored at ⁇ 80° C. for cytokine analyses.
  • concavalin A Con A 50 ⁇ g/mL
  • beta-lactoglobulin 100 ⁇ g/mL BLG
  • ovalbumin 100
  • the cytokines were quantified in culture supernatants with a human multiplex, particle-based, flow cytometric assay. TNF- ⁇ , IFN- ⁇ , IL-1 ⁇ , IL-2, IL-4, IL-10, GM-CSF, G-CSF concentrations in the supernatants were directly measured without further dilution. To determine IL-6, IL-8, MCP-1 and MIP-1 ⁇ supernatants were diluted 1:10 in RPMI. The differences in cytokine expression, as compared to the negative control, were determined and concentrations were normalized to the number of lymphocytes (for IL-2) and total leukocytes (for all other cytokines) obtained from whole blood count (pg/ml/10E3 cells).
  • CB CD4 + T helper (Th) cells and CD8 + T cytotoxic (Tc) cells predominantly expressed the na ⁇ ve (CD45RA + ) phenotype (>84%) while less than 13% expressed CD45RO + .
  • the ratio of CD4 + /CD8 + as well as the percentages of CD4 + CD45RA + , CD8 + CD45RA + , CD4 + CD45RO + and CD4 + CD45RO + did not differ significantly between the prebiotic and the placebo groups.
US12/282,302 2006-03-10 2007-03-09 Use of non-digestable sacharides for giving an infant the best start after birth Abandoned US20090305996A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06110973.2 2006-03-10
EP06110973 2006-03-10
EP06112822 2006-04-20
EP06112822.9 2006-04-20
PCT/NL2007/050094 WO2007105945A2 (en) 2006-03-10 2007-03-09 Use of non-digestable sacharides for giving an infant the best start after birth

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2007/050094 A-371-Of-International WO2007105945A2 (en) 2006-03-10 2007-03-09 Use of non-digestable sacharides for giving an infant the best start after birth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/593,822 Continuation US9872869B2 (en) 2006-03-10 2015-01-09 Use of non-digestible saccharides for giving an infant the best start after birth

Publications (1)

Publication Number Publication Date
US20090305996A1 true US20090305996A1 (en) 2009-12-10

Family

ID=38349460

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/282,302 Abandoned US20090305996A1 (en) 2006-03-10 2007-03-09 Use of non-digestable sacharides for giving an infant the best start after birth
US14/593,822 Active 2028-03-05 US9872869B2 (en) 2006-03-10 2015-01-09 Use of non-digestible saccharides for giving an infant the best start after birth

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/593,822 Active 2028-03-05 US9872869B2 (en) 2006-03-10 2015-01-09 Use of non-digestible saccharides for giving an infant the best start after birth

Country Status (16)

Country Link
US (2) US20090305996A1 (zh)
EP (2) EP1993577B1 (zh)
JP (1) JP2009529574A (zh)
CN (2) CN103315205A (zh)
AR (1) AR059817A1 (zh)
AU (2) AU2007225549B2 (zh)
BR (1) BRPI0708701A2 (zh)
CA (2) CA2883256A1 (zh)
DK (1) DK1993577T3 (zh)
ES (1) ES2459621T3 (zh)
MY (2) MY191118A (zh)
NZ (1) NZ571158A (zh)
PL (1) PL1993577T3 (zh)
PT (1) PT1993577E (zh)
RU (1) RU2462252C2 (zh)
WO (1) WO2007105945A2 (zh)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100260720A1 (en) * 2007-12-17 2010-10-14 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
EP2454948A1 (en) * 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
DE102011012494A1 (de) * 2011-02-25 2012-08-30 Humana Milchunion Eg Prebiotische Kohlenhydrat-Zusammensetzungen
US8703737B2 (en) 2010-12-31 2014-04-22 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US8802650B2 (en) 2010-12-31 2014-08-12 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
US9283240B2 (en) 2010-12-31 2016-03-15 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
WO2016043583A1 (en) * 2014-09-15 2016-03-24 N.V. Nutricia Reducing anxiety in progeny
WO2016139330A1 (en) * 2015-03-05 2016-09-09 Nestec S.A. Compositions for use in improving stool consistency or frequency in infants or young children
US9539269B2 (en) 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US9763970B2 (en) 2010-12-31 2017-09-19 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
US9795623B2 (en) 2010-12-31 2017-10-24 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin C and anti-inflammatory agents
US9872869B2 (en) 2006-03-10 2018-01-23 N. V. Nutricia Use of non-digestible saccharides for giving an infant the best start after birth
WO2018215189A1 (en) * 2017-05-24 2018-11-29 Nestec S.A. Hmos blends for use in infants or young children for health purposes
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US11337990B2 (en) 2010-12-31 2022-05-24 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
RU2773404C2 (ru) * 2017-05-24 2022-06-03 Сосьете Де Продюи Нестле С.А. Смеси олигосахаридов грудного молока (огм) для применения у младенцев или детей младшего возраста в медицинских целях
US11446316B2 (en) 2011-07-22 2022-09-20 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080126195A1 (en) 2004-07-22 2008-05-29 Ritter Andrew J Methods and Compositions for Treating Lactose Intolerance
PT2217246E (pt) * 2007-11-08 2015-02-10 Nestec Sa Utilização de oligossacáridos contendo n-acetil-lactosamina para maturação de respostas imunes em recém-nascidos
US9119414B2 (en) 2007-12-07 2015-09-01 N.V. Nutricia Bifidobacterium for dust mite allergy
US8961953B2 (en) * 2008-03-14 2015-02-24 Nestec S.A. Synbiotic mixture
EP2348890B1 (en) * 2008-03-28 2013-09-18 Nestec S.A. Probiotics for use in expecting female mammals for enhancing the immunity of their offsprings
EP2110027A1 (en) * 2008-04-01 2009-10-21 Nestec S.A. Long-chain polyunsaturated fatty acids (LC-PUFA) in maternal nutrition during pregnancy and lactation
CN107320480A (zh) 2009-02-24 2017-11-07 里特制药股份有限公司 益生素制剂和使用方法
WO2011008087A1 (en) * 2009-07-15 2011-01-20 N.V. Nutricia Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
PL2453902T3 (pl) 2009-07-15 2014-01-31 Nutricia Nv Mieszanina niepodatnych na trawienie oligosacharydów do stymulowania układu immunologicznego
EP2563372A4 (en) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc PREBIOTIC FORMULATIONS AND METHODS OF USE
EP2465508A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases
EP2465507A1 (en) * 2010-11-23 2012-06-20 Nestec S.A. Oligosaccharide composition for treating skin diseases
WO2012092155A1 (en) * 2010-12-31 2012-07-05 Abbott Laboratories Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
WO2012177118A1 (en) * 2011-06-22 2012-12-27 N.V. Nutricia Method for reducing the occurrence of infection in young children
NL2007268C2 (en) 2011-08-16 2013-02-19 Friesland Brands Bv Nutritional compositions comprising human milk oligosaccharides and uses thereof.
EP2811845B1 (en) * 2012-02-10 2015-12-09 N.V. Nutricia Maternal supplement to enhance immune system of an infant
CN110301646A (zh) * 2012-03-27 2019-10-08 雅培制药有限公司 用于使用人乳寡糖调节细胞介导的免疫的方法
EP2842560A4 (en) * 2012-04-23 2015-12-02 Univ Kyoto COMPOSITION FOR PROMOTING BIFIDOBACTERIUM GROWTH
MX2016013064A (es) * 2014-04-08 2017-01-26 Abbott Lab Metodos para mejorar las respuestas inmune innata y/o deteccion de patogenos de la mucosa mediante oligosacaridos de la leche humana.
AU2016303000B2 (en) * 2015-08-04 2021-01-21 Société des Produits Nestlé S.A. Nutritional compositions with 2FL and LNnT for use in inducing a gut microbiota close to the one of breast fed infants
EP3377071B1 (en) 2015-11-17 2024-01-10 Glycom A/S Human milk oligosaccharides for treating antibiotic associated complications
EP3407878A1 (en) * 2016-01-26 2018-12-05 Nestec S.A. Composition for preventing or reducing transepidermal water loss
AU2017230187A1 (en) * 2016-03-11 2018-10-04 Infinant Health, Inc A transient commensal microorganism for improving gut health
AU2018229814B2 (en) * 2017-03-08 2023-06-01 N.V. Nutricia Composition with non-digestible oligosaccharides for attenuating nasal epithelial inflammation
WO2019031961A1 (en) 2017-08-11 2019-02-14 N.V. Nutricia OLIGOSACCHARIDE OF HUMAN MILK TO IMPROVE PHYSICAL IMMUNE CONDITION
EP3672600A4 (en) 2017-08-21 2021-05-19 Glycom A/S SYNTHETIC COMPOSITION TO REDUCE ALLERGY SYMPTOMS
WO2019232513A1 (en) * 2018-06-01 2019-12-05 Evolve Biosystems, Inc. Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires
TW202128190A (zh) * 2019-10-24 2021-08-01 荷蘭商弗里斯蘭康必奶荷蘭有限公司 用於預防氣喘的包含2’-岩藻糖基乳糖之組成物
KR20220107011A (ko) * 2019-11-29 2022-08-01 글리콤 에이/에스 임산부의 미생물총을 개선하기 위한 hmo의 혼합물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032399A (en) * 1985-04-17 1991-07-16 Sherwood L. Gorbach L. acidophilus strains
US20040062758A1 (en) * 2001-01-25 2004-04-01 Annika Mayra-Makinen Combination of probiotics
US20050153018A1 (en) * 2002-03-12 2005-07-14 Nestec S.A. Probiotic delivery system
US20060233772A1 (en) * 2005-04-15 2006-10-19 Udo Herz Method for preventing or treating the development of respiratory allergies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9401644A (nl) 1994-10-06 1996-05-01 Friesland Brands Bv Voedingsmiddel voor zwangere en lacterende vrouwen
GB9808579D0 (en) * 1998-04-22 1998-06-24 Novartis Nutrition Ag Improvements in or relating to organic compounds
DE19836339B4 (de) * 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
RU2132695C1 (ru) * 1998-12-10 1999-07-10 Кричков Андрей Германович Средство для профилактики токсикоза первой половины беременности эйр-1
FI110668B (fi) 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
RU2213493C2 (ru) * 2001-05-29 2003-10-10 Устинова Александра Васильевна Консервы на мясной основе для питания беременных и кормящих женщин
US6596313B2 (en) * 2001-08-06 2003-07-22 The Quigley Corporation Nutritional supplement and methods of using it
DE10147100A1 (de) * 2001-09-25 2003-04-17 Numico Res B V Antiinfektive Kohlenhydrate
RU2262867C2 (ru) * 2002-02-14 2005-10-27 Катков Юрий Адольфович Бад к пище для улучшения репродукции человека (варианты)
AU2003242763B2 (en) * 2002-06-28 2008-02-21 Biosearch, S.A. Probiotic strains, a process for the selection of them, compositions thereof, and their use
NZ537821A (en) * 2002-08-06 2007-05-31 The Quigley Corp Anti-viral compositions useful for treating one or more adverse effects of viral infections
WO2004105607A2 (en) 2003-05-23 2004-12-09 Sonamed Corporation Ear probe and disposable ear tip system
CA2530437C (en) * 2003-06-23 2011-11-15 Nestec S.A. Nutritional formula for optimal gut barrier function
US8557794B2 (en) * 2003-10-24 2013-10-15 N.V. Nutricia Immunemodulating oligosaccharides
ES1056525Y (es) * 2004-01-13 2004-07-16 Perez Alfredo Pineiro Halador de tres rodillos para redes y aparejos de pesca.
CN1562049A (zh) * 2004-04-02 2005-01-12 聂四平 低聚果糖在制备治疗及预防阴道炎药中的应用
EP1597978A1 (en) * 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US7303745B2 (en) * 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
RU2462252C2 (ru) 2006-03-10 2012-09-27 Н.В. Нютрисиа Применение неусвояемых сахаридов для лучшей адаптации младенцев после рождения

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032399A (en) * 1985-04-17 1991-07-16 Sherwood L. Gorbach L. acidophilus strains
US20040062758A1 (en) * 2001-01-25 2004-04-01 Annika Mayra-Makinen Combination of probiotics
US20050153018A1 (en) * 2002-03-12 2005-07-14 Nestec S.A. Probiotic delivery system
US20060233772A1 (en) * 2005-04-15 2006-10-19 Udo Herz Method for preventing or treating the development of respiratory allergies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Constipation" by BabycareAdvice.com. Retrieved on 8/7/2014. Published on 9/20/2004. Retrieved online at *
Gibson, G.R., Rabiu, B., Rycroft, C.E., Rastall, R.A. (2003) "Trans-Galactooligosaccharides as Prebiotics" in HANDBOOK OF FUNCTIONAL DAIRY PRODUCTS. Edited by Colette Shortt and John O'Brien, published by CRC Press, p. 91-108. *
Kolida, S., Tuohy, K., Gibson, G.R. (2002) Prebiotic effects of inulin and oligofructose. British Journal of Nutrition, vol. 87, Suppl. 2, p. S193-S197. *
Van Loo, J.A.E. (2004) Prebiotics Promote Good Health. The Basis, the Potential, and the Emerging Evidence. Journal of Clinical Gastroenterology, vol. 38, supp. 2, p. S70-S75. *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9872869B2 (en) 2006-03-10 2018-01-23 N. V. Nutricia Use of non-digestible saccharides for giving an infant the best start after birth
US20100260720A1 (en) * 2007-12-17 2010-10-14 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
US9217133B2 (en) * 2007-12-17 2015-12-22 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
US9854826B2 (en) 2010-11-23 2018-01-02 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
EP2454948A1 (en) * 2010-11-23 2012-05-23 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
WO2012069416A1 (en) * 2010-11-23 2012-05-31 Nestec S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
US10716321B2 (en) 2010-11-23 2020-07-21 Societe Des Produits Nestle S.A. Oligosaccharide mixture and food product comprising same
AU2011333861B2 (en) * 2010-11-23 2015-09-03 Société des Produits Nestlé S.A. Oligosaccharide mixture and food product comprising this mixture, especially infant formula
US11197875B2 (en) 2010-12-31 2021-12-14 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US11311562B2 (en) 2010-12-31 2022-04-26 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
US11701376B2 (en) 2010-12-31 2023-07-18 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
US11690859B2 (en) 2010-12-31 2023-07-04 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US9539269B2 (en) 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US9763970B2 (en) 2010-12-31 2017-09-19 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
US9795623B2 (en) 2010-12-31 2017-10-24 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin C and anti-inflammatory agents
US9808474B2 (en) 2010-12-31 2017-11-07 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US9283240B2 (en) 2010-12-31 2016-03-15 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
US8802650B2 (en) 2010-12-31 2014-08-12 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
US11654156B2 (en) 2010-12-31 2023-05-23 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US10369164B2 (en) 2010-12-31 2019-08-06 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US10471081B2 (en) 2010-12-31 2019-11-12 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US11633412B2 (en) 2010-12-31 2023-04-25 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US10709720B2 (en) 2010-12-31 2020-07-14 Abbott Laboratories Human milk oligosaccharides for modulating inflammation
US8703737B2 (en) 2010-12-31 2014-04-22 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US11524018B2 (en) 2010-12-31 2022-12-13 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US11464793B2 (en) 2010-12-31 2022-10-11 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US10813940B2 (en) 2010-12-31 2020-10-27 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection
US11337990B2 (en) 2010-12-31 2022-05-24 Abbott Laboratories Human milk oligosaccharides to promote growth of beneficial bacteria
US10973837B2 (en) 2010-12-31 2021-04-13 Abbott Laboratories Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof
US11179406B2 (en) 2010-12-31 2021-11-23 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
US11207335B2 (en) 2010-12-31 2021-12-28 Abbott Laboratories Methods of using human milk oligosaccharides for improving airway respiratory health
DE102011012494A1 (de) * 2011-02-25 2012-08-30 Humana Milchunion Eg Prebiotische Kohlenhydrat-Zusammensetzungen
US11446316B2 (en) 2011-07-22 2022-09-20 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
US10639319B2 (en) 2011-08-29 2020-05-05 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
WO2016043583A1 (en) * 2014-09-15 2016-03-24 N.V. Nutricia Reducing anxiety in progeny
US10821124B2 (en) 2015-03-05 2020-11-03 Societe Des Produits Nestle S.A. Compositions for use in improving stool consistency or frequency in infants or young children
RU2731154C2 (ru) * 2015-03-05 2020-08-31 Сосьете Де Продюи Нестле С.А. Композиция для применения в улучшении консистенции или частоты стула у младенцев или детей младшего возраста
RU2731067C2 (ru) * 2015-03-05 2020-08-28 Сосьете Де Продюи Нестле С.А. Композиция для применения в улучшении консистенции или частоты стула у младенцев или детей младшего возраста
WO2016139329A1 (en) * 2015-03-05 2016-09-09 Nestec S.A. Compositions for use in improving stool consistency or frequency in infants or young children
WO2016139330A1 (en) * 2015-03-05 2016-09-09 Nestec S.A. Compositions for use in improving stool consistency or frequency in infants or young children
US11260067B2 (en) 2017-05-24 2022-03-01 Societe Des Produits Nestle S.A. Methods and compositions for decreasing concentrations of detrimental proteolytic metabolites, treating health disorders, and/or promoting health benefits in infants or young children
RU2773404C2 (ru) * 2017-05-24 2022-06-03 Сосьете Де Продюи Нестле С.А. Смеси олигосахаридов грудного молока (огм) для применения у младенцев или детей младшего возраста в медицинских целях
WO2018215189A1 (en) * 2017-05-24 2018-11-29 Nestec S.A. Hmos blends for use in infants or young children for health purposes

Also Published As

Publication number Publication date
DK1993577T3 (da) 2014-05-12
AR059817A1 (es) 2008-04-30
MY191118A (en) 2022-05-30
CA2883256A1 (en) 2007-09-20
ES2459621T3 (es) 2014-05-12
US20150250807A1 (en) 2015-09-10
MY168792A (en) 2018-12-04
PT1993577E (pt) 2014-05-27
AU2007225549A1 (en) 2007-09-20
WO2007105945A2 (en) 2007-09-20
WO2007105945A3 (en) 2007-11-08
US9872869B2 (en) 2018-01-23
AU2007225549B2 (en) 2012-09-27
NZ571158A (en) 2011-08-26
RU2008140167A (ru) 2010-04-20
CN101420966B (zh) 2013-07-17
BRPI0708701A2 (pt) 2011-06-07
CN103315205A (zh) 2013-09-25
AU2012265617B2 (en) 2016-02-25
PL1993577T3 (pl) 2014-07-31
EP1993577B1 (en) 2014-02-12
JP2009529574A (ja) 2009-08-20
CA2645472C (en) 2015-09-15
RU2462252C2 (ru) 2012-09-27
CN101420966A (zh) 2009-04-29
AU2012265617A1 (en) 2013-01-10
EP1993577A2 (en) 2008-11-26
EP2388010A1 (en) 2011-11-23
CA2645472A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
US9872869B2 (en) Use of non-digestible saccharides for giving an infant the best start after birth
RU2478309C2 (ru) Применение сфингомиелина и неперевариваемых углеводов для нормализации микробиоты кишечника
RU2437581C2 (ru) Способ стимуляции целостности кишечного барьера после родов не через естественные родовые пути
AU2014278835B2 (en) Synbiotic composition for treatment of infections in allergic patients
US20100063002A1 (en) Method of improving skills with a composition comprising non-digestible saccharide
TW201233334A (en) Human milk oligosaccharides to promote growth of beneficial bacteria
AU2014367412B2 (en) Lactobacillus salivarius for the treatment of mastitis
KR20120061836A (ko) 알레르기 예방 및 치료용 프로바이오틱 유래의 비-생육가능성 물질
TW201208583A (en) Nutritional compositions
CN113613510A (zh) 包含2’岩藻糖基乳糖和3’半乳糖基乳糖的营养组合物
US20240100075A1 (en) Synthetic Compositions Comprising LNFP III and LSTa
BR112016013904B1 (pt) Uso da cepa de lactobacillus salivarius, composição, e, uso de uma composição

Legal Events

Date Code Title Description
AS Assignment

Owner name: N.V. NUTRICIA, NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEERMANN, CHRISTOPHER;KNOL, JAN;ALLES, MARTINE SANDRA;AND OTHERS;REEL/FRAME:022897/0612;SIGNING DATES FROM 20080922 TO 20080930

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION